XML 122 R19.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Stock-based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2019
Share-based Payment Arrangement [Abstract] |
Stock-based Compensation | Note 11 Stock-based Compensation The Amended and Restated Omnibus Stock and Performance Compensation Plan (the “Omnibus Plan”) provides incentive opportunities for key employees and non-employee directors and to align the personal financial interests of such individuals with those of the Company’s shareholders. The Omnibus Plan permits the issuance of up to 1,500,000 shares of the Company’s common stock in the form of stock options, SARs, restricted stock, restricted stock units and performance awards. 50 Table of Contents Restricted Stock Restricted shares granted prior to April 16, 2013 are amortized to expense over the three-year vesting period. Beginning on April 16, 2013, restricted shares granted to Company employees are amortized to expense over the three-year annual vesting period whereas restricted shares granted to members of the Board of Directors are amortized to expense over a one-year service period, with the exception of those shares granted in lieu of cash payment for retainer fees which are expensed in the period earned. Beginning on February 2, 2017, restricted shares granted to Company employees are amortized to expense over the three-year cliff vesting period. Changes in restricted shares outstanding for the year ended December 31, 2019 were as follows:
|  | Shares |  |  | Weighted Average Grant Date Fair Value
Balance at December 31, 2018 |  | 99,724 |  |  | $45.48
Granted |  | 36,812 |  |  | 49.30
Vested |  | (13,264 | ) |  | 39.76
Balance at December 31, 2019 |  | 123,272 |  |  | $47.24
During 2018 and 2017, 35,000 and 31,277 shares, respectively, were granted with weighted average per share market values at date of grant of $49.79 in 2018 and $49.55 in 2017. The fair value of such shares are based on the market price on the date of grant. Amortization of the restricted stock bonus awards totaled $1,551,000 for 2019, $1,571,000 for 2018 and $1,743,000 for 2017. As of December 31, 2019, the total unrecognized compensation expense related to non-vested restricted stock awards was $1,438,000 and the related weighted average period over which it is expected to be recognized is approximately 1.07 years. The total fair value of shares vested during the years ended December 2019, 2018, and 2017 was $527,000, $1,112,000, and $1,389,000, respectively. Performance-Based Restricted Stock In February 2017, the Company granted three-year PBRS awards which are contingent upon the Company’s achievement of pre-established financial goals over the period from January 1, 2017 through December 31, 2019. The PBRS awards cliff vest on the three year anniversary of their grant date at levels ranging from 0% to 150% of the target opportunity based on the actual achievement of financial goals for the three-year performance period. The aggregate target number of PBRS shares granted was 30,388 with an average grant date fair value of $49.33 per share. The 2019 expense related to these grants totaled $583,000 and is based on the grant date fair value of the awards and the Company’s achievement of 118% of the target financial goals. The estimated expense for 2019 and each future period through the vesting date is subject to prospective adjustment based upon changes in the expected achievement of the financial goals. In each of February and July 2018, the Company granted three-year PBRS awards which are contingent upon the Company’s achievement of pre-established financial goals over the period from January 1, 2018 through December 31, 2020. The PBRS awards cliff vest on the three-year anniversary of their grant date at levels ranging from 0% to 150% of the target opportunity based on the actual achievement of financial goals for the three-year performance period. The aggregate target number of PBRS shares granted was 35,602 with an average grant date fair value of $49.04 per share. The 2019 expense related to these grants totaled $674,000 and is based on the grant date fair value of the awards and the Company’s achievement of 117% of the target financial goals. The estimated expense for 2019 and each future period through the vesting date is subject to prospective adjustment based upon changes in the expected achievement of the financial goals. In each of February and June 2019, the Company granted three-year PBRS awards which are contingent upon the Company’s achievement of pre-established financial goals over the period from January 1, 2019 through December 31, 2021. The PBRS awards cliff vest on the three-year anniversary of their grant date at levels ranging from 0% to 150% of the target opportunity based on the actual achievement of financial goals for the three-year performance period. The aggregate target number of PBRS shares granted was 36,801 with an average grant date fair value of $49.06 per share. The 2019 expense related to these grants totaled $593,000 and is based on the grant date fair value of the awards and the Company’s achievement of 108% of the target financial goals. The estimated expense for 2019 and each future period through the vesting date is subject to prospective adjustment based upon changes in the expected achievement of the financial goals. SARs During 2019, there were no SARs granted and no expense recognized. As of December 31, 2019, there was no unrecognized compensation expense related to SARs. 51 Table of Contents Changes in SARs outstanding for the year ended December 31, 2019 were as follows:
|  | SARs |  |  | Weighted Average Exercise Price
Balance at December 31, 2018 |  | 237,121 |  |  |  |  | $29.86
Exercised |  | (81,829 | ) |  |  |  | 24.71
Forfeited |  | — |  |  |  |  | —
Balance at December 31, 2019 |  | 155,292 |  |  |  |  | 32.58
Exercisable at December 31, 2019 |  | 155,292 |  |  |  |  | $32.58
The total intrinsic value of SARs exercised during 2019 and 2018 was $2,022,000 and $1,110,000, respectively. The average remaining contractual term for SARs outstanding as of December 31, 2019 was 2.92 years, and the aggregate intrinsic value was $3,908,000. The average remaining contractual term for SARs exercisable as of December 31, 2018 was 3.50 years, and the aggregate intrinsic value was $5,468,000. The total compensation cost for share-based payment arrangements was $3,144,000, $3,006,000, and $2,340,000, in 2019, 2018, and 2017, respectively.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration